Market Newsdesk

EPA certification is a critical milestone to allow shipping vehicles to customers;



Company’s first Class 3 EV Cab Chassis Trucks began rolling off the production line on Aug. 21, 2023

BREA, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — via IBN — Mullen Automotive Inc. (NASDAQ: MULN) (“Mullen” or the “Company”), an emerging electric vehicle (“EV”) manufacturer, today announces its achievement of a key milestone with full approval from the Environmental Protection Agency (“EPA”) with certification for Class 3 EV Commercial Vehicles received on Sept. 22, 2023. Class 3 vehicle production began in August 2023 with the first vehicles rolling off the assembly line on Aug. 21, 2023.

In addition, the Mullen Class 3 EV Cab Chassis Truck has completed all required testing requirements for Federal Motor Vehicle Safety Standards (“FMVSS”) and compliance. With EPA certification in-hand and FMVSS compliance, Mullen can now begin shipments of Class 3 EVs for customer deliveries.

Mullen previously announced on May 2, 2023, a Class 3 vehicle order with Randy Marion Automotive (“RMA”) for 1,000 all-electric cab chassis trucks valued at $63 million. In addition, it was announced on May 11, 2023, that MGT Lease Company (“MGT”), a national fleet leasing provider, will purchase 250 Class 3 EV cab chassis trucks under a contract valued at $15.7 million. On Aug. 28, 2023, Mullen also received an order for Class 3 EV trucks from NRTC Automation Group.

“I am extremely proud of this important milestone and, now with EPA certification and FMVSS in-hand, we are planning to begin Class 3 deliveries this week. Mullen is fully committed to our vision and plan and is focusing in now on deliveries to our customers,” said David Michery, CEO and chairman of Mullen Automotive.

The Mullen THREE is an efficient Class 3 low cab forward EV truck featuring a tight turning diameter of 38 feet and excellent visibility for superior maneuverability on narrow city streets. This versatile chassis provides a clean top-of-rail for easy upfitting with bodies up to 14 feet long and over 5,800 pounds of payload. In addition, the design of the LCF chassis allows more cargo volume within a given overall length.

Mullen THREE Vehicle Highlights:

• 130-mile estimated range
• 11,000 lbs. GVWR
• 5,802 lbs. max payload
• 14 ft. max box length
• 38 ft. turning diameter

View full vehicle specifications for the Mullen THREE here.

For further details on EPA certification, including 8-K filling, please visit MullenUSA.com.

About Mullen

Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.

To learn more about the Company, visit www.MullenUSA.com.

Forward-Looking Statements

Certain statements in this press release that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential” and similar expressions are intended to identify such forward-looking statements. All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Mullen and are difficult to predict. Examples of such risks and uncertainties include but are not limited to the timing of delivery and order completion of the Class 3 vehicles and whether the Class 3 will be a success. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K filed by Mullen with the Securities and Exchange Commission. Mullen anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Mullen assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law. Forward-looking statements speak only as of the date they are made and should not be relied upon as representing Mullen’s plans and expectations as of any subsequent date.

Contact:
Mullen Automotive, Inc.
+1 (714) 613-1900
www.MullenUSA.com

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

Attachment

• The Mullen THREE, Class 3 EV Cab Chassis Truck, starting at $68,500 MSRP, before available federal tax incentives

ATHENS, Greece, Sept. 25, 2023 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ASL Bulk Marine Limited for one of its Ultramax dry bulk vessels, the m/v DSI Pyxis. The gross charter rate is US$14,250 per day, minus a 5% commission paid to third parties, for a period until minimum October 10, 2024 up to maximum December 10, 2024. The charter commenced on September 24, 2023.

The “DSI Pyxis” is a 60,362 dwt Ultramax dry bulk vessel built in 2018.

The Company also announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with ST Shipping and Transport Pte. Ltd., for one of its Kamsarmax dry bulk vessels, the m/v Maia. The gross charter rate is US$13,500 per day, minus a 5% commission paid to third parties, for a period until minimum June 15, 2024 up to maximum August 20, 2024. The charter commenced on September 23, 2023.

The “Maia” is a 82,193 dwt Kamsarmax dry bulk vessel built in 2009.

The employments of “DSI Pyxis” and “Maia” are anticipated to generate approximately US$8.91 million of gross revenue for the minimum scheduled periods of the time charters.

Diana Shipping Inc.’s fleet currently consists of 41 dry bulk vessels: 4 Newcastlemax, 10 Capesize, 5 Post-Panamax, 6 Kamsarmax, 7 Panamax and 9 Ultramax. As of today, the combined carrying capacity of the Company’s fleet is approximately 4.7 million dwt with a weighted average age of 10.48 years. A table describing the current Diana Shipping Inc. fleet can be found on the Company’s website, www.dianashippinginc.com. Information contained on the Company’s website does not constitute a part of this press release.

About the Company

Diana Shipping Inc. is a global provider of shipping transportation services through its ownership and bareboat charter-in of dry bulk vessels. The Company’s vessels are employed primarily on short to medium-term time charters and transport a range of dry bulk cargoes, including such commodities as iron ore, coal, grain and other materials along worldwide shipping routes.

Cautionary Statement Regarding Forward-Looking Statements

Matters discussed in this press release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts.

The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. The words “believe,” “anticipate,” “intends,” “estimate,” “forecast,” “project,” “plan,” “potential,” “may,” “should,” “expect,” “pending” and similar expressions identify forward-looking statements.

The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions, including without limitation, Company management’s examination of historical operating trends, data contained in the Company’s records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond the Company’s control, the Company cannot assure you that it will achieve or accomplish these expectations, beliefs or projections.

In addition to these important factors, other important factors that, in the Company’s view, could cause actual results to differ materially from those discussed in the forward-looking statements include the continuing impacts of the COVID-19 pandemic; the strength of world economies and currencies, general market conditions, including fluctuations in charter rates and vessel values, changes in demand for dry bulk shipping capacity, changes in the Company’s operating expenses, including bunker prices, drydocking and insurance costs, the market for the Company’s vessels, availability of financing and refinancing, changes in governmental rules and regulations or actions taken by regulatory authorities, potential liability from pending or future litigation, general domestic and international political conditions, including risks associated with the continuing conflict between Russia and Ukraine and related sanctions, potential disruption of shipping routes due to accidents or political events, vessel breakdowns and instances of off-hires and other factors. Please see the Company’s filings with the U.S. Securities and Exchange Commission for a more complete discussion of these and other risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. 

GLEN MILLS, Pa., Sept. 25, 2023 (GLOBE NEWSWIRE) — Axalta Coating Systems Ltd. (NYSE: AXTA) (“Axalta” or the “Company”), a leading global coatings company, today announced that Brian Berube has decided to retire as Senior Vice President, General Counsel & Corporate Secretary at the end of this year. Alex Tablin-Wolf, who currently serves as Vice President and Associate General Counsel, has been appointed his successor effective January 1, 2024. Mr. Tablin-Wolf will become Senior Vice President, General Counsel and Corporate Secretary at that time, reporting directly to Axalta CEO and President, Chris Villavarayan.

“On behalf of our Board and the entire organization, I want to thank Brian for his exceptional legal expertise and guidance that has proven instrumental in enabling Axalta’s success now and in the future,” said Mr. Villavarayan, CEO and President. “He has been a trusted advisor, valued partner and strong steward for the Company, with contributions well beyond legal counsel. His passion for strong corporate governance and ethical leadership is embedded in a global Legal team that will continue a commitment to integrity while supporting Axalta’s growth. We wish him all the best in his upcoming retirement.”

“This transition is enabled by strong bench strength, and we are fortunate to have someone internally with Alex’s caliber and global experience to step in and lead our global Legal organization,” added Mr. Villavarayan. “Alex has deep knowledge of Axalta’s business and has helped advance many key strategic initiatives during his time with the company. I am confident he will uphold the integrity of our governance framework and will be a strategic advisor to our Board and a strong addition to our Executive Committee.”

About Alex Tablin-Wolf

Tablin-Wolf joined Axalta in January 2017, and currently serves as Vice President and Associate General Counsel. He previously served as an associate in the corporate and securities practice groups of Fox Rothschild LLP and Blank Rome LLP. Tablin-Wolf earned his bachelor’s degree in psychology from Santa Clara University and his J.D., cum laude, from the Temple University Beasley School of Law.

About Axalta

Axalta is a global leader in the coatings industry, providing customers with innovative, colorful, beautiful, and sustainable coatings solutions. From light vehicles, commercial vehicles and refinish applications to electric motors, building facades and other industrial applications, our coatings are designed to prevent corrosion, increase productivity, and enhance durability. With more than 150 years of experience in the coatings industry, the global team at Axalta continues to find ways to serve our more than 100,000 customers in over 130 countries better every day with the finest coatings, application systems and technology. For more information, visit axalta.com and follow us on Facebook, LinkedIn and @axalta on Twitter.

WESTLAKE VILLAGE, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of an educational campaign designed to elevate understanding, connection, and encouragement for those living with seborrheic dermatitis, or Seb Derm for short. The campaign, Clearing Up Seb Derm, features expert advice from leading dermatologists and personal stories from individuals living with seborrheic dermatitis.

Clearing Up Seb Derm sheds light on the lack of information and understanding of seborrheic dermatitis, and how this condition has an impact beyond the skin, affecting people’s everyday lives. The campaign also aims to raise awareness that Seb Derm symptoms can vary from person to person, may look different across body areas and skin tones, and can sometimes be confused with other skin conditions.

“Seborrheic dermatitis is a common inflammatory skin condition that affects an estimated 10 million Americans. Seborrheic dermatitis can affect anyone, and for Black/African Americans patients, it is the third most common skin condition seen in the dermatology clinic,” said Andrew Alexis, M.D., Vice-Chair for Diversity and Inclusion for the Department of Dermatology and Dermatologist at Weill Cornell Medicine, who serves as a consultant for Arcutis Biotherapeutics. “In richly pigmented skin, seborrheic dermatitis can present differently than in lightly pigmented skin. For example, patients with skin of color often present with lighter colored patches on the cheeks, eyebrows, or hairline with or without visible redness or scaling. This campaign can help raise awareness and understanding of Seb Derm across various skin types.”

Many people with Seb Derm report that the condition has a significant impact on their appearance, personal hygiene routine, anxiety levels, embarrassment, clothing choices, and quality of sleep. Despite the significant impact on a person’s life, a 2022 online Harris Poll survey of over 300 adults living with Seb Derm showed that 63% of people didn’t think their symptoms were severe enough to warrant medical attention.

“There is a common misconception that Seb Derm is a hygiene issue, but in actuality, it’s a real medical condition that can significantly impact an individual’s quality of life. People who experience seborrheic dermatitis are often reluctant and embarrassed to discuss their symptoms and to seek care,” said Geeta Yadav, M.D., and Founder of FACET Dermatology. “The survey found that on average, it takes individuals 3.6 years from the appearance of symptoms to visit a healthcare provider. We have options to help individuals with Seb Derm, but the first step is to visit a healthcare provider who can provide a clinical diagnosis and treatment plan.”

As someone living with Seb Derm, Christina Sims understands the embarrassment this skin condition can cause, and wants people to remember they’re not alone.

“I waited about six months before I went to see my dermatologist about my symptoms because I could not find information online. After my diagnosis, I felt so alone and embarrassed. Through sharing my story online, I was able to find and connect with other people experiencing the same thing,” said Christina, a personal brand and marketing strategist, and entrepreneur. “That’s why I’ve partnered with Arcutis for this campaign. We aim to provide educational resources about Seb Derm so people can feel empowered to see their healthcare provider sooner, as well as encourage those suffering from Seb Derm to connect with each other through a site specifically designed to help build a sense of community.”

“Seb Derm is a highly visible skin condition, and often appears on the face, where it’s difficult to hide symptoms like flaking and redness. The associated social stigma that comes with Seb Derm is an added challenge for individuals to take the initiative to seek diagnosis and care,” said Patrick Burnett, M.D., Ph.D., FAAD, Chief Medical Officer at Arcutis. “Through Clearing Up Seb Derm, Arcutis hopes to encourage people to speak with their healthcare providers sooner, rather than later, so they can get the appropriate treatment, care, and support that they need.”

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Clearing Up Seb Derm

For more information about this initiative, visit http://www.clearingupsebderm.com/.

About Arcutis

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio that harnesses our unique dermatology development platform coupled with our dermatology expertise to build differentiated therapies against biologically validated targets. Arcutis’ dermatology development platform includes a robust pipeline with multiple clinical programs for a range of inflammatory dermatological conditions including scalp and body psoriasis, atopic dermatitis, seborrheic dermatitis, and alopecia areata. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, and X.

Contacts:

Media

Amanda Sheldon, Head of Corporate Communications
[email protected]

Investors

Eric McIntyre, Head of Investor Relations
[email protected]

Gourmet, USDA Organic fermented sauces, to be carried in all St. Louis metropolitan area Dierbergs locations extending Edible Garden’s Midwest presence

Consumers in St. Louis to experience ‘Bland to Bold’ Pulp organic sauces, reflecting Edible Garden’s dedication to flavor and sustainability

BELVIDERE, NJ, Sept. 25, 2023 (GLOBE NEWSWIRE) —
Edible Garden AG Incorporated (“Edible Garden” or the “Company”)
(Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), locally grown, organic, and sustainable produce and products, today announced that Dierbergs Markets will begin carrying Edible Garden’s new line of Pulp sustainable gourmet USDA Organic fermented sauces in all 26 of their greater St. Louis metropolitan-area stores and one location at Missouri’s Lake of the Ozarks. 

Edible Garden’s new line of Pulp sustainable gourmet sauces available at Dierbergs Markets

Mr. Jim Kras, Chief Executive Officer of Edible Garden, stated, “We are pleased that Dierbergs Markets will begin carrying our Pulp Sustainable Gourmet Sauces across their entire retail network in the St. Louis metropolitan area. The inclusion of Dierbergs enhances our distribution reach throughout the Midwest region of the United States. We believe their relative proximity to our new Edible Garden Heartland facility in Grand Rapids, Michigan will allow the Company to service them with ease, further leveraging the additional capacity created as a result of the opening of the facility last year. In addition, customers in the St Louis metropolitan area with a strong affinity for tasty, sustainable, and USDA Organic fermented products will now have an opportunity to purchase these ‘Bland to Bold’ Pulp sustainable sauces and taste them for themselves.”

“This move to produce sustainable, gourmet sauces underscores our dedication to sustainability and product innovation. The Pulp line epitomizes our commitment to both environmental responsibility and culinary excellence. As we further our geographical reach, more consumers will have the chance to experience the unique flavors and benefits of our products. Dierbergs Markets, with its strong reputation in the St. Louis metropolitan area, is an ideal partner for this endeavor. Their dedication to quality aligns seamlessly with our Zero-Waste Inspired® mission and values. This collaboration, coming on the heels of our recent agreement with Morton-Williams Supermarkets, highlights Edible Garden’s building momentum in this product category. Feedback that we have already received from retailers and consumers across our distribution network has been extremely positive and we look forward to announcing similar agreements in the near future. Looking ahead, the Company remains committed to our core values and mission, and we eagerly anticipate the opportunities the future holds for Edible Garden and our loyal customers.”

For more information on Pulp click here.

ABOUT EDIBLE GARDEN®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), locally grown, organic and sustainable produce and products backed by Zero-Waste Inspired® next generation farming. Offered at over 4,000 stores in the US, Edible Garden is disrupting the CEA and sustainability technology movement with its safety-in-farming protocols, use of sustainable packaging, patented GreenThumb software and self-watering in-store displays. The Company currently operates its own state-of-the-art greenhouses and processing facilities in Belvidere, New Jersey and Grand Rapids, Michigan, and has a network of contract growers, all strategically located near major markets in the U.S. Its proprietary GreenThumb 2.0 patented (US Nos.: US 11,158,006 B1 and US 11,410,249 B2) software optimizes growing in vertical and traditional greenhouses while seeking to reduce pollution-generating food miles. Edible Garden is also a developer of ingredients and proteins, providing an accessible line of plant and whey protein powders under the Vitamin Way® and Vitamin Whey® brands. In addition, the Company offers a line of sustainable food flavoring products such as Pulp gourmet sauces and chili-based products. For more information on Edible Garden go to https://ediblegardenag.com/.

Forward-Looking Statements

This press release contains forward-looking statements, including with respect to the Company’s overall profitability, ability to expand its distribution network and distribution relationships, and performance as a public company. The words “anticipate,” “believe,” “expect,” “looking ahead,” “objective,” “will,” “seek,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including market and other conditions and the Company’s ability to achieve its growth objectives. The Company undertakes no obligation to update any such forward-looking statements after the date hereof to conform to actual results or changes in expectations, except as required by law.

Investor Contacts:

Crescendo Communications, LLC
212-671-1020
[email protected]

Attachment

• Edible Garden’s new line of Pulp sustainable gourmet sauces available at Dierbergs Markets

CULVER CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Calling all Swifties! Reading Cinemas, an affiliate of Reading International, Inc. (NASDAQ: RDI), is ushering fans into a VIP concert movie experience with Taylor Swift: The Eras Tour, opening on Friday, Oct. 13. Following pop icon Taylor Swift as she performs her biggest hits in the record-breaking concert, the film is setting records of its own with advance ticket sales making beautiful box office music for Reading Cinemas.

“The response to the movie weeks from opening is a testament to Taylor Swift’s fanbase enthusiasm,” said Jennifer Deering, division manager for Reading Cinemas. “Since going on sale, our pre-sales for this concert event are the highest for any movie or event we have exhibited in 2022 and 2023. We are delighted to provide our guests with a variety of opportunities to be further immersed into this unforgettable experience, including exclusive food and beverage specials at participating locations.”

Sure to strike a chord with audiences, Reading Cinemas will offer complimentary limited edition mini one sheets of the movie poster to Taylor Swift: The Eras Tour moviegoers on a first-come, first-served basis, while supplies last. Uniquely designed and highly collectible cups and popcorn tubs commemorating the epic movie event will be available for purchase at the concession counter, also while supplies last.

Reading Cinemas is offering movie and concert lovers an exclusive viewing experience via private watch parties, providing Swifties the chance to sing and dance alongside friends and family while viewing the film in their own VIP auditorium. Available from Thursday, Oct. 19, through Sunday, Nov. 5, each watch party will accommodate up to 40 guests and currently may be booked at ReadingCinemasUS.com or the Reading Cinemas US App.

Reading Cinemas is also announcing an upcoming 72-hour E-Gift Card flash sale. Those purchasing a $100 E-Gift Card any time from Monday, Sept. 25, at 12:01 a.m. (local time) through Wednesday, Sept. 27, at 11:59 p.m. (local time), will also receive a $30 Bonus E-Gift Card. Available on the Reading Cinemas website and mobile app, the e-cards may be redeemed at both the box office and concession stand allowing movie lovers to indulge in traditional movie fare or choose something from each theater’s chef-inspired food and beverage menu while enjoying the film of their choice.

The e-cards may be used for Taylor Swift: The Eras Tour and other scheduled concert films such as CARLOS: The Santana Journey Global Premiere (Sept. 23, 24 & 27 at select locations) and K-LOVE Live at Red Rocks (Nov. 6 & 7 at select locations), as well as a slate of other highly anticipated films including Martin Scorsese’s Killers of the Flower Moon, Marvel Studios’ The Marvels, Migration from Illumination Studios, DC Comics’ Aquaman and the Lost Kingdom, Hunger Games: The Ballad of Songbirds and Snakes and the animated musical fantasy Wish from Walt Disney Animation Studios.

Guests will also be able to enjoy upcoming holiday-themed signature programming such as Horror Fest, Four Weeks of Christmas, and a Christmas-themed Pajama Party providing fun for the entire family.

Get the all-access scoop on tickets, showtimes, and more via the Reading Cinemas US App and website at www.ReadingCinemasUS.com. For more information on bookings and available showtimes, or to inquire about arranging larger parties, guests should contact the theater.

About Reading International, Inc.


Reading International, Inc. (NASDAQ: RDI), an internationally diversified cinema and real estate company, is a leading entertainment and real estate company, engaged in the development, ownership and operation of cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. The family of Reading brands includes cinema brands: Reading Cinemas, Angelika Film Centers, Consolidated Theatres, and the State Cinema in Tasmania; live theatres operated by Liberty Theatres in New York City; and signature property developments, including Newmarket Village, Cannon Park, and The Belmont Common in Australia, Courtenay Central in New Zealand, and 44 Union Square in New York City.

Additional information about Reading can be obtains at the Company’s website www.ReadingRDI.com.

Cautionary Note Regarding Forward-Looking Statements


This press release contains forward-looking statements within the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “may,” “will,” “expect,” “believe,” “intend,” “future,” and “anticipate” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our expectations regarding the size of the box office of the concert movie in the Consolidated circuit.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include those factors discussed throughout Part I, Item 1A – Risk Factors and Part II, Item 7 – Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Annual Report on Form 10-K for the most recently ended fiscal year and our other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statement made by us in this Press Release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

For investor information contact:

Reading International, Inc.
Gilbert Avanes, Executive Vice President & Chief Financial Officer
Andrzej Matyczynski, Executive Vice President – Global Operations
(213) 235-2240

For media information contact:

Jo Ellen Brantferger
(214) 435-1936

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced the appointment of Caren Deardorf as the Company’s first Chief Commercial and Strategy Officer. Ms. Deardorf will build and lead Editas Medicine’s commercial organization, strategy, and execution to support all launch, commercialization, and lifecycle management activities of the Company’s current and future pipeline of products.

“As we drive our lead program EDIT-301 towards commercialization, I am happy to welcome a commercial leader of Caren’s caliber to Editas. Caren has a proven ability to translate early discovery and clinical assets into robust business strategy with disciplined portfolio prioritization and value creation. Additionally, she has led multiple successful US and global product launches. Caren’s expertise and track record make her the ideal leader to help Editas reach this goal for patients,” said Gilmore O’Neill, M.B., M.M.Sc., President and Chief Executive Officer, Editas Medicine.

Ms. Deardorf added, “With a clear focus on bringing EDIT-301 into the market for people living with sickle cell disease, ‘right now’ is the optimal time for Editas to build a commercial team and strategy. I look forward to driving the business forward alongside this strong Leadership Team as we bring EDIT-301 – and future pipeline medicines – through the clinic to commercialization.”

Caren Deardorf brings to Editas more than 25 years of international biotechnology leadership across a range of companies and therapeutic areas. Most recently, Ms. Deardorf served as the Chief Commercial Officer of Magenta Therapeutics. Prior to Magenta, she served as the Chief Commercial Officer of Ohana Biosciences where she was responsible for developing a commercial strategy, including planning for the company’s first product launch.

Earlier in her career, Ms. Deardorf held a variety of commercial roles of increasing responsibility at Biogen, most recently serving as Vice President, Product Development & Commercialization, leading and executing a highly successful global launch of SPINRAZA^®, a treatment for children and adults with spinal muscular atrophy. During her tenure at Biogen, Ms. Deardorf was instrumental in building the multiple sclerosis (MS) franchise and helping to establish Biogen’s global leadership through US and worldwide brand management, including leading the brand and launch strategy for TECFIDERA^® and the successful US and EU launches of TYSABRI^® and AVONEX^®.

Ms. Deardorf holds a Bachelor of Science degree in biology from Tufts University and a Master of Business Administration from the Olin Graduate School of Business at Babson College. Ms. Deardorf serves on the Boards of Directors for Crinetics Pharmaceuticals and for NeuroSense Therapeutics. She is also a board member for the Pan-Mass Challenge, a non-profit organization that raises funds for Dana-Farber Center Institute.

About Editas Medicine
As a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Forward-Looking Statements

This press release contains forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “target,” “should,” “would,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation and completion of preclinical studies and clinical trials, and clinical development of the Company’s product candidates; availability and timing of results from preclinical studies and clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or the results of future trials; expectations for regulatory approvals to conduct trials or to market products and availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. These and other risks are described in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Report on Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’s subsequent filings with the Securities and Exchange Commission, and in other filings that the Company may make with the Securities and Exchange Commission in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a4cdbf9-9748-4d22-95b6-c03e4665de73

PALO ALTO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (“PDL”) effective October 1, 2023.

As Indiana is a Single PDL State, where the five Indiana Managed Medicaid plans (Anthem, CareSource, MDwise, Managed Health Services (MHS), and UnitedHealthcare) must follow the State PDL, this change improves access to Elyxyb for all eligible patients under the Indiana Medicaid umbrella, the combined traditional Medicaid and Managed Medicaid populations, totaling approximately 1.2M lives, between the ages of 18-64.

Under the new terms, Elyxyb will be Preferred with the following prior authorization (PA) criteria:

• Migraine Dx, 18 & Older
• Trial and failure of 1 preferred triptan or contraindication to triptans
• Elyxyb will have a QL of 6 bottles.

“We are pleased to announce our first Elyxyb managed health care win with the Medicaid plan in Indiana, which we believe is an important step to expand utilization of Elyxyb throughout the U.S. Importantly, our diversified portfolio of unique, leading programs will increasingly allow us to offer patients complementary and standalone opioid-sparing outpatient pain management solutions,” said Jaisim Shah, Chief Executive Officer of Scilex Holding Company.

About Scilex Holding Company

Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R. Program for SEMDEXA^TM, its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex participated in the type C meeting for purposes of pre-NDA discussion with the FDA and is pending official minutes in writing from the FDA. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain.  Scilex launched its first commercial product ZTlido® in October 2018, in-licensed a commercial product Gloperba® in June 2022, and launched its third FDA-approved product Elyxyb^TM in April 2023. It is also developing its late-stage pipeline, which includes a pivotal Phase 3 candidate, and one Phase 2 and one Phase 1 candidate.  Its commercial product, ZTlido® (lidocaine topical system) 1.8%, or ZTlido®, is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with post-herpetic neuralgia, which is a form of post-shingles nerve pain.  Scilex in-licensed the exclusive right to commercialize Gloperba® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex in-licensed the exclusive rights to commercialize Elyxyb^TM (celecoxib oral solution) in the U.S. and Canada, the only FDA-approved ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults. Scilex launched Elyxyb^TM in April 2023, and is planning to commercialize Gloperba® by 2024, and is well-positioned to market and distribute those products.   Scilex’s three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous gel product containing 10 mg dexamethasone), or SEMDEXA™, a Phase 3, novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, with FDA Fast Track status; SP-103 (lidocaine topical system) 5.4%, a Phase 2 study, triple-strength formulation of ZTlido®, for the treatment of acute low back pain, with FDA Fast Track status; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia that has completed multiple Phase 1 trial programs and is expected to initiate Phase 2 trials in 2024.

Scilex Holding Company is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potential growth of Elyxyb in managed care plans, the potential benefits related to the addition of Elyxyb to the State of Indiana Medicaid PDL, Scilex’s belief that it is well positioned to continue its growth over the next several years, Scilex’s long-term objectives and commercialization plans, Scilex’s potential to attract new capital, future opportunities for Scilex, Scilex’s future business strategies, the expected cash resources of Scilex and the expected uses thereof; Scilex’s current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity; statements regarding ZTlido®, Gloperba®, ELYXYB®, SP-102 (SEMDEXA™), SP-103 or SP-104, if approved by the FDA; Scilex’s development and commercialization plans; and Scilex’s products, technologies and prospects.  

Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets and whether a market will be established for Scilex’s common stock; general economic, political and business conditions; risks related to the ongoing COVID-19 pandemic; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials for SP-103 or SP-104 may not be successful; risks that the prior results of the clinical trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: [email protected]

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB® is the subject of an exclusive, transferable license to use the trademark by Scilex Holding Company.

All other trademarks are the property of their respective owners.

© 2023 Scilex Holding Company All Rights Reserved.